|
Synonyms: BAR-502 | NorECDCOH
Compound class:
Synthetic organic
Comment: BAR502 is a semi-synthetic steroidal agonist of farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (GPBAR1) [1]. It also activates MRGPRX4 [4], and has antagonist activity at the leukemia inhibitory factor receptor (LIF) receptor [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. D'Amore C, Di Leva FS, Sepe V, Renga B, Del Gaudio C, D'Auria MV, Zampella A, Fiorucci S, Limongelli V. (2014)
Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. J Med Chem, 57 (3): 937-54. [PMID:24387325] |
|
2. Di Giorgio C, Bellini R, Lupia A, Massa C, Bordoni M, Marchianò S, Rosselli R, Sepe V, Rapacciuolo P, Moraca F et al.. (2023)
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma. Front Oncol, 13: 1140730. [PMID:36998446] |
|
3. Festa C, Renga B, D'Amore C, Sepe V, Finamore C, De Marino S, Carino A, Cipriani S, Monti MC, Zampella A et al.. (2014)
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. J Med Chem, 57 (20): 8477-95. [PMID:25247751] |
|
4. Yeager A, Selfridge B, Sainz M, Martinborough E, Boehm M, Huang L. (2020)
Modulators of mas-related g-protein receptor x4 and related products and methods. Patent number: WO2020198537A1. Assignee: Escient Pharmaceuticals Inc. Priority date: 26/03/2020. Publication date: 01/10/2020. |